
ADiTx Therapeutics ADTX
$ 0.97
0.01%
Quarterly report 2025-Q2
added 08-14-2025
ADiTx Therapeutics EV - Enterprise Value 2011-2026 | ADTX
Annual EV - Enterprise Value ADiTx Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23.1 M | 28.4 M | 2.8 M | -1.25 M | 17.3 M | 2.97 M | 1.65 M | 84.9 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 28.4 M | -1.25 M | 9.39 M |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
1.82 B | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
436 M | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
5.52 M | - | 5.93 % | $ 314 M | ||
|
Albireo Pharma
ALBO
|
417 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
33.1 M | - | 10.36 % | $ 9.8 M | ||
|
I-Mab
IMAB
|
8.28 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.95 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
525 M | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
849 M | $ 220.94 | 2.51 % | $ 5 B | ||
|
Aptinyx
APTX
|
-18.3 M | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
4.79 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
3.41 B | - | -1.52 % | $ 24.7 M | ||
|
MediWound Ltd.
MDWD
|
32 M | $ 17.08 | 2.83 % | $ 465 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
1.92 B | $ 19.7 | 2.44 % | $ 921 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-9.16 M | - | - | $ 26.5 M | ||
|
Mesoblast Limited
MESO
|
1.4 B | $ 15.54 | 8.48 % | $ 10.1 B | ||
|
Ayala Pharmaceuticals
AYLA
|
5.32 M | - | - | $ 7.46 M | ||
|
AgeX Therapeutics
AGE
|
6.28 M | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
-13.2 M | - | -24.86 % | $ 820 K | ||
|
Atreca
BCEL
|
94.8 M | - | -11.76 % | $ 5.79 M | ||
|
Acasti Pharma
ACST
|
24 M | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
-720 M | - | 0.49 % | $ 251 B | ||
|
Mirum Pharmaceuticals
MIRM
|
5.68 B | $ 90.9 | 3.44 % | $ 4.56 B | ||
|
bluebird bio
BLUE
|
270 M | - | - | $ 546 M | ||
|
Институт стволовых клеток человека
ISKJ
|
14.1 M | - | - | - | ||
|
Cara Therapeutics
CARA
|
71.1 M | - | -3.03 % | $ 260 M | ||
|
Adverum Biotechnologies
ADVM
|
125 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
38.2 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
-3.02 M | - | -9.65 % | $ 45.9 M | ||
|
MediciNova
MNOV
|
42.4 M | $ 1.44 | -0.68 % | $ 70.7 M | ||
|
Avenue Therapeutics
ATXI
|
-1.23 M | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
1.11 B | $ 1.36 | 3.03 % | $ 347 M | ||
|
CytomX Therapeutics
CTMX
|
971 M | $ 4.41 | 3.98 % | $ 608 M | ||
|
Cyclacel Pharmaceuticals
CYCC
|
8.71 M | - | -5.98 % | $ 34.1 M | ||
|
ChemoCentryx
CCXI
|
91.4 M | - | - | $ 3.74 B | ||
|
Merck & Co.
MRK
|
296 B | $ 118.9 | 2.17 % | $ 297 B | ||
|
Dynavax Technologies Corporation
DVAX
|
2.02 B | - | - | $ 2.02 B | ||
|
BioDelivery Sciences International
BDSI
|
445 M | - | -4.8 % | $ 255 M | ||
|
Enochian Biosciences
ENOB
|
145 M | - | - | $ 40.5 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-23.2 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
3.19 B | - | - | $ 867 M | ||
|
Bellerophon Therapeutics
BLPH
|
77.1 M | - | -74.18 % | $ 955 K | ||
|
Akero Therapeutics
AKRO
|
2.99 B | - | - | $ 3.67 B | ||
|
Neurocrine Biosciences
NBIX
|
665 M | $ 131.82 | 3.1 % | $ 13.1 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
847 M | $ 4.56 | 5.68 % | $ 874 M | ||
|
Homology Medicines
FIXX
|
-28.5 M | - | 0.77 % | $ 53.4 M | ||
|
Akouos
AKUS
|
95.1 M | - | 0.23 % | $ 488 M | ||
|
AIkido Pharma
AIKI
|
22.8 M | - | 1.93 % | $ 17.4 M | ||
|
Allakos
ALLK
|
122 M | - | - | $ 28.6 M |